The current "instruments and tools used to assess the value of cancer medicines may be too “blunt” to capture the true potential of future therapies and technologies to treat small patient populations, says a discussion paper released by Rare Cancers Australia. …
Latest Video
New Stories
-
Data analytics more important than ever as Australia prepares for pandemic
March 30, 2020 - - Latest News -
Dr Brendan Shaw: Change has been constant but not like this
March 30, 2020 - - Comment -
COVID-19: Sector seeks partial relief from competition law
March 30, 2020 - - Latest News -
Uncertainty in response to lockdown in India
March 30, 2020 - - Latest News -
Shawview formally establishes a local presence
March 30, 2020 - - Latest News -
COVID-19: New dispensing regulation and PHARMAC finally responds to stockpiling
March 27, 2020 - - Latest News -
Fifteen global biopharmaceutical companies announce COVID-19 R&D collaboration
March 27, 2020 - - Latest News